HPV Vaccine in Adolescents

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Human papillomavirus (HPV) is the primary cause of cervical cancer and other anogenital and oropharyngeal cancers worldwide.
• Prophylactic HPV vaccines are available and have demonstrated efficacy in reducing HPV prevalence and disease.
• The 9-valent HPV vaccine is currently available in the US, covering 90% of HPV-attributable cancers.

Purpose of the Study:

• To review the efficacy and current status of HPV vaccination.
• To highlight the importance of HPV vaccination in cancer prevention.
• To discuss strategies for improving HPV vaccination rates in the United States.

Main Methods:

• Review of existing studies on HPV vaccine efficacy and impact.
• Analysis of HPV vaccination rates in the US compared to other adolescent vaccines.
• Discussion of current public health strategies for vaccine uptake.

Main Results:

• HPV vaccines are safe and effective, with no evidence of waning protection.
• Two doses of HPV vaccine are sufficient if administered before age 15.
• HPV vaccination rates in the US are lower than those for other routine adolescent vaccines.

Conclusions:

• HPV vaccination is a critical tool for preventing HPV-related cancers.
• Strategies to increase vaccination rates include strong clinician recommendations and addressing missed opportunities.
• Continued efforts are needed to ensure widespread HPV immunization for optimal public health outcomes.